Anaeze Offodile II was named chief strategy officer at Memorial Sloan Kettering Cancer Center. He will begin his role on May 1.
Francisco Sanchez-Vega was awarded the Corning-MSK Health Equity Research Fellowship, a two-year grant that funds research into the broad disparities in cancer outcomes for patients in historically underserved communities.
Data from the phase III DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, were published in The New England Journal of Medicine. Results from this study were previously presented at the European Society for Medical Oncology Congress in September 2022.
Selwyn M. Vickers wants Memorial Sloan Kettering Cancer Center to become better known in Harlem, Coney Island, and other parts of New York City where the elite institution he now leads is not a go-to place.
Memorial Sloan Kettering Cancer Center has been granted a two-year merit extension of its Cancer Center Support Grant from NCI. The grant is MSK’s oldest and largest, and the one which provides its designation as one of 53 Comprehensive Cancer Centers nationwide.
Some job relocations are less cumbersome than others. When Jedd Wolchok left Memorial Sloan Kettering Cancer Center after more than a quarter century, he crossed East 68th Street to Weill Cornell campus, where he is now the director of the Sandra and Edward Meyer Cancer Center.
Patients with metastatic non-small cell lung cancer who are matched to targeted therapy live longer when liquid biopsies are used to detect genomic alterations in circulating tumor DNA that aren’t picked up by tissue sequencing, according to a study published Nov. 10 in Nature Medicine.
The Houston Astros beat the New York Yankees in the American League Championship Series, settling a Twitter bet between MD Anderson and Memorial Sloan Kettering’s presidents Peter W.T. Pisters and Selwyn M. Vickers.
MD Anderson Cancer Center President Peter W.T. Pisters challenged Selwyn M. Vickers, president and CEO of Memorial Sloan Kettering Cancer Center, to a friendly Twitter bet.
Researchers from Memorial Sloan Kettering Cancer Center have discovered subclonal co-mutations and immunophenotypic profiles that can distinguish individual cells indicative of future AML relapse from others present after treatment using Mission Bio Inc.’s Tapestri Single-cell Multi-omics Measurable Residual Disease assay.
